Related references
Note: Only part of the references are listed.Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase
SI Hashemy et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers
RK Ramanathan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Advances toward an understanding of brainstem gliomas
SS Donaldson et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas - Results of a French Society of Paediatric Oncology Phase II study
V Bernier-Chastagner et al.
CANCER (2005)
Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstern gliomas
RJ Packer et al.
CANCER (2005)
Population pharmacokinetics of motexafin gadolinium in adults with brain metastases or glioblastoma multiforme
DR Miles et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: Results of a randomized phase III trial
CA Meyers et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases
MP Mehta et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: Centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points
MP Mehta et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases
P Carde et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
